ArticleHealth affairs (Project Hope)2025
Association Between Medicaid Prescription Drug Caps And Antiretroviral Adherence Among People Living With HIV.
Article in Health affairs (Project Hope), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medication and Acute Care Use in Young Adults With Opioid Use Subject to Medicaid Prescription Caps.JAMA health forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To control spending, some state Medicaid agencies "cap" the number of prescriptions that a beneficiary can fill each month, presenting a potential barrier to medication adherence for people with chronic health conditions. To evaluate the association between Medicaid prescription drug cap policies and antiretroviral therapy (ART) adherence among people living with HIV, we compared beneficiaries in four states with caps to beneficiaries in eight states without caps during the period 2016-19. In three of four cap states, cap status was associated with a 9 percent relative reduction in the percentage of days covered by ART over the course of twelve months compared to noncap states, and a 24 percent relative reduction in the likelihood of achieving optimal ART adherence (90 percent or higher) over the course of twelve months. The association was stronger for people with higher baseline ART adherence or more baseline comorbidities. We also identified racial and ethnic disparities, where the magnitude of ART adherence reduction associated with caps was significantly greater for Black and Hispanic people than for White people. Medicaid prescription drug cap policies appear to be both a potential source of racial and ethnic disparity and an impediment to achieving clinical targets for optimal ART adherence among people with HIV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.